Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Flucytosine + TG4023||Phase I||Actionable||In a Phase I trial, TG4023 and Flucytosine combination therapy demonstrated safety and preliminary efficacy, resulted in stable disease in 50% (8/16) of patients with advanced solid tumors (PMID: 28177438; NCT00978107).||28177438|